JPRN-UMIN000019736
Completed
N/A
The examination of the efficacy by adverse reaction changing the treatment with Oxybutynin or Mirabegron on the patient who cannot go on treatment with anticholinergic agent - The examination of the efficacy by adverse reaction changing the treatment with Oxybutynin or Mirabegron on the patient who cannot go on treatment with anticholinergic agent
Department of Urology, Shiga University of medical science0 sites15 target enrollmentNovember 10, 2015
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Department of Urology, Shiga University of medical science
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •contraindication of the medicine acute urinary retension within 12 months residual urine over 100mL urinary infection a1 blacker within 4 weeks
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 3
Evaluation of the effect of Medvac IVIg on PIDPrimary immunodeficiency disorder.D84.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.D84.9IRCT20101012004920N9Medvac BioPharma Company50
Completed
N/A
Assessment of treatment efficacy and adverse effects of Microrelin in patient with prostate cancer.IRCT201109067457N4Pooyesh darou company40
Active, Not Recruiting
Phase 2
W-JHS MM01JPRN-jRCTs071180011Shibayama Hirohiko80
Completed
N/A
Evaluation of efficacy and safety of a response adapted therapy adding bortezomib in newly diagnosed, transplant ineligible multiple myeloma patients with insufficient efficacy by lenalidomide - dexamethasone (Rd) therapy.Multiple myelomaJPRN-UMIN000026498Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu80
Not Yet Recruiting
N/A
Comparision Of Efficay And Adverse Effects Of Two Topicals In Treatment Of Localised Alopecia Areata - METHOTREXATE ONE PERCENTAGE GEL TOFACITINIB Versus TWO PERCENTAGE GEHealth Condition 1: L638- Other alopecia areataCTRI/2024/06/069460DR M Yashaswini